The BRAFV600E mutation and larger tumor size are linked to increased maximum, mean, and peak FDG uptake values on 18FFDG-PET/CT in patients with recurrent PTC. These findings improve understanding of mutation-associated metabolic behavior in recurrent PTC; however, they do not support changes in clinical management or risk stratification based solely on FDG PET/CT metrics or BRAFV600E status. Further research should investigate the potential of 18FFDG-PET/CT metrics as biomarkers for guiding individualized treatment strategies in BRAFV600E-positive PTC.
Bastian et al. (Sun,) studied this question.